Brava Cardiac Panel

Brava is developing a point-of-care cardiac panel for the emergency department.

  • High-sensitivity troponin to diagnose or rule-out heart attack
  • NT-proBNP for the diagnosis and prognosis of heart failure
  • D-dimer to diagnose or rule out pulmonary embolism (clots in the lungs) in patients with shortness of breath

High-Sensitivity Troponin for Heart Attack

Our first test in the cardiac marker product line will be a NextGen test for heart attack: a high-sensitivity troponin  test that will enable faster diagnosis of heart attack or rule-out/discharge of low-risk patients. Safe discharge reduces unnecessary hospital admissions, reduces crowding in the emergency department and cuts costs to the healthcare system significantly.

The Need

Emergency physicians need sensitive, precise lab results, ideally within 15 minutes, to guide treatment or safe discharge for patients with chest pain or other symptoms of acute coronary syndrome. New guidelines from the European Society of Cardiology and the American College of Cardiology are driving the shift to high-sensitivity troponin assays. High sensitivity tests have been proven to diagnose or rule-out heart attack 4-6 hours earlier than contemporary assays. Central lab tests suffer from turnaround time of more than an hour. Point-of-care tests are widely used, but the, care team must compromise performance for speed. Neither lab nor current point-of-care tests meet the need.

Brava can fill this large market gap with a high-sensitivity troponin test that delivers lab-quality performance at the point-of-care in 15 minutes. The LightDeck platform enables precise measurements at very low concentrations.

Clinical Utility of High-Sensitivity Troponin

The video highlights results of the High STEACS and HiSTORIC trials.

Conclusions: High sensitivity troponin can accelerate rule-out of NSTEMI,  which reduces admissions, eases ED crowding and saves money for health systems.

Heart Failure Assessment

Approximately 6.2 million Americans have heart failure, there are 1 million new cases diagnosed each year and over 78,000 deaths annually. Prevalence will increase to more than 8 million people by 2030 and the total cost of heart failure is expected to grow to nearly $70 billion in the U.S. as the population ages.

With statistics like these, emergency departments need better tools to assess patients with shortness of breath and other symptoms of heart failure. We are developing a 3-plex test with high-sensitivity troponin, NT-proBNP and D-dimer in the Brava Cardiac Panel that will deliver actionable results in 15 minutes.


Pulmonary embolism (PE) is a life-threating blood clot in the lung, usually arising from deep vein thrombosis (DVT), or clots in the legs. A D-dimer test can be used to rule out PE or DVT.

Ready to find out more?

Let's talk!